Inovalon Holdings Inc (INOV) was Downgraded by Robert W. Baird to ” Neutral” while Lowering the Price Target of the company shares to $ 21 from a previous price target of $22 . Earlier the firm had a rating of “Outperform ” on the company shares. Robert W. Baird advised their investors in a research report released on Apr 21, 2016.
Many Wall Street Analysts have commented on Inovalon Holdings Inc. Inovalon Holdings Inc was Downgraded by Morgan Stanley to ” Underweight” on Mar 30, 2016. KeyBanc Capital Mkts Initiated Inovalon Holdings Inc on Mar 29, 2016 to “Overweight”, Price Target of the shares are set at $26.
On the company’s financial health, Inovalon Holdings Inc reported $0.13 EPS for the quarter, based on the information available during the earnings call on Feb 25, 2016. Analyst had a consensus estimate of $0.13. The company had revenue of $120.60 million for the quarter, compared to analysts expectations of $125.40 million. The company’s revenue was up 34.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 EPS.
Inovalon Holdings Inc opened for trading at $18.89 and hit $19.4 on the upside on Monday, eventually ending the session at $19.1, with a gain of 1.22% or 0.23 points. The heightened volatility saw the trading volume jump to 3,19,496 shares. Company has a market cap of $2,898 M.
In a different news, on Mar 7, 2016, Robert A Wychulis (President) sold 33,003 shares at $18.17 per share price. According to the SEC, on Dec 10, 2015, Daniel L Rizzo (Chief Innovation Officer) sold 24,000 shares at $20.00 per share price. On Dec 7, 2015, Shauna L Vernal (Chief Legal Officer) sold 33,437 shares at $18.55 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovalon Holdings Inc. is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans hospitals physicians patients pharmaceutical companies and researchers. Through its datasets integration technologies predictive analytics and subject matter expertise the Company delivers platforms. Its analytics identify gaps in care quality data integrity and financial performance while providing clients with capabilities to resolve these gaps. The Company’s data analytics and intervention platforms consist of four primary components: data integration advanced analytics intervention platforms and business processing. This system manages the process of defining and configuring industry data feeds from its clients and partners including electronic health records laboratory pharmacy patient reported claims paper based medical records biometric and hospital data feeds.